According to a market report by Lucintel, the future of the global patient-derived xenograft model market looks promising with opportunities in the pharmaceutical & biopharmaceutical company, academic & research institute, and CRO & CDMO markets. The global patient-derived xenograft model market is expected to grow with a CAGR of 9.6% from 2025 to 2031. The major drivers for this market are the increasing demand for personalized cancer research, the rising adoption of preclinical oncology models, and the growing focus on targeted drug development.
A more
than 150-page report to understand trends, opportunity and forecast in global patient-derived
xenograft model market to 2031 by tumor type (lung cancer, pancreatic cancer,
prostate cancer, breast cancer, and others), model type (mice model and rat
model), end use (pharmaceutical & biopharmaceutical companies, academic
& research institutes, and CRO’s & CDMO’s), and region (North America,
Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that, within the tumor type category, breast cancer is expected to
witness the highest growth over the forecast period.
Within the
end use category, CRO & CDMO is expected to witness the highest growth.
Download
sample by clicking on patient-derived
xenograft model market.
In terms
of region, North America is expected to witness the highest growth over the
forecast period.
Charles
River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs,
Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. are the
major suppliers in the patient-derived
xenograft model market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment